Patents by Inventor Carolina Lanter
Carolina Lanter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8980938Abstract: The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: GrantFiled: December 18, 2008Date of Patent: March 17, 2015Assignee: SanofiInventors: Stephanie Hachtel, Juergen Dedio, Josef Pernerstorfer, Stephen Shimshock, Carolina Lanter
-
Patent number: 8642643Abstract: The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: GrantFiled: December 18, 2008Date of Patent: February 4, 2014Assignee: SanofiInventors: Stephanie Hachtel, Juergen Dedio, Josef Pernerstorfer, Stephen Shimshock, Carolina Lanter, Raymond Kosley
-
Patent number: 8552033Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: GrantFiled: December 17, 2008Date of Patent: October 8, 2013Assignee: SANOFIInventors: Stephanie Hachtel, Juergen Dedio, Stephen Shimshock, Carolina Lanter
-
Patent number: 7994168Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.Type: GrantFiled: February 21, 2007Date of Patent: August 9, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, James Spoonamore, Gregory Merriman, Joseph T Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang, Martin Smrcina
-
Patent number: 7652007Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.Type: GrantFiled: February 13, 2004Date of Patent: January 26, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
-
Publication number: 20090258936Abstract: The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: ApplicationFiled: December 18, 2008Publication date: October 15, 2009Applicant: SANOFI-AVENTISInventors: Stephanie HACHTEL, Juergen DEDIO, Josef PERNERSTORFER, Stephen SHIMSHOCK, Carolina LANTER
-
Publication number: 20090258906Abstract: The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: ApplicationFiled: December 18, 2008Publication date: October 15, 2009Applicant: SANOFI-AVENTISInventors: Stephanie HACHTEL, Juergen DEDIO, Josef PERNERSTORFER, Stephen SHIMSHOCK, Carolina LANTER, Raymond KOSLEY
-
Publication number: 20090215827Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: ApplicationFiled: December 17, 2008Publication date: August 27, 2009Applicant: SANOFI-AVENTISInventors: Stephanie HACHTEL, Juergen DEDIO, Stephen SHIMSHOCK, Carolina LANTER
-
Publication number: 20080090854Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: ApplicationFiled: June 29, 2007Publication date: April 17, 2008Applicant: Sanofi-Aventis Deutschland GmbHInventors: Stephanie HACHTEL, Juergen DEDIO, Holger HEITSCH, Werngard Czechtizky, Sven Grueneberg, Stephen Shimshock, Raymond Kosley, Carolina Lanter, Hui Li, Rosy Sher, Aleksandra Weichsel
-
Publication number: 20070197539Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicamentsType: ApplicationFiled: February 21, 2007Publication date: August 23, 2007Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, Martin Smrcina, James Spoonamore, Gregory Merriman, Joseph Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
-
Publication number: 20050085483Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.Type: ApplicationFiled: February 13, 2004Publication date: April 21, 2005Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang